With a strong US launch pipeline, benign price erosion and focus on complex generics, Lupin sits on tracks for a robust growth trajectory. However, th see more...
year on year results are good, but quarter on quarter results are not encouraging. how market reacts tomorrow is very difficult to gauge considering t see more...
MARKET VIEW
OUTLOOK
SECTORS
STRATEGY
VIEW
PERSONAL FINANCE
INSURANCE
INVEST
MUTUAL FUND
GENERAL